Charles River Laboratories Intl. Inc vs FedEx Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while FedEx Corporation trades at $291.66 (market cap $69.04B). The key difference: FedEx Corporation is far larger — about 4.9× Charles River Laboratories Intl. Inc's market cap, and FedEx Corporation pays a 1.67% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and FedEx Corporation for 87 Days on average.
| CRL | FDX | |
|---|---|---|
Market Cap | $14.23B | $69.04B |
Volume | 1,176,885 | 1,287,367 |
Sector | Health | Industrials |
52-Week High | $310.77 | $339.35 |
52-Week Low | $149.93 | $180.87 |
Typical Hold Time | 33 Days | 87 Days |
Enterprise Value | $17.06B | $98.68B |
Dividend Yield | — | 1.67% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
FDX trades at $290.98, up 0.67% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $6.31 exceeding the $5.96 estimate. Revenue for 2025 was $87.93 billion, with a net income margin of 4.68%. Recent news includes a $300 million order for electric trucks from Harbinger and shareholder approval of executive compensation.
The outlook is mixed: analyst consensus is bullish with a $307.55 price target, but rising fuel costs and geopolitical tensions pose near-term risks. Earnings growth and cost-cutting initiatives support upside, while margin pressure from higher diesel prices and competitive pressures are key concerns for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →